| Completed | Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis | Phase 1 | 2023-07-12 |
| Completed | ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects Fungal Disease | Phase 1 | 2022-12-14 |
| Terminated | A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Candidiasis, Invasive, Candidemia | Phase 3 | 2022-08-03 |
| Recruiting | Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis | — | 2022-07-28 |
| Completed | Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Vulvovaginal Candidiasis | Phase 3 | 2022-05-01 |
| Completed | ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects Fungal Infection | Phase 1 | 2019-12-05 |
| Completed | Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects Pharmacokinetics | Phase 1 | 2019-11-22 |
| Completed | Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis Recurrent Vulvovaginal Candidiasis | Phase 3 | 2019-10-21 |
| Completed | Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects Pharmacokinetics | Phase 1 | 2019-09-09 |
| Completed | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasi Candida Vulvovaginitis | Phase 3 | 2019-06-07 |
| Terminated | Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invas Invasive Pulmonary Aspergillosis | Phase 2 | 2019-01-22 |
| Completed | Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasi Candida Vulvovaginitis | Phase 3 | 2019-01-04 |
| Completed | Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidia Candidiasis, Invasive, Candidemia | Phase 3 | 2017-11-15 |
| Completed | Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Can Candida Vulvovaginitis | Phase 2 | 2017-08-01 |
| Completed | Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractor Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis | Phase 3 | 2017-04-01 |
| Completed | Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidi Vulvovaginal Candidiasis | Phase 2 | 2015-11-01 |
| Completed | Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candid Mycoses, Candidiasis, Invasive, Candidemia | Phase 2 | 2014-09-01 |
| Completed | Study of SCY-635, Pegasys and Copegus in Hepatitis C Hepatitis C Infection | Phase 2 | 2010-11-01 |
| Completed | Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients Chronic Hepatitis C | Phase 1 | 2007-04-01 |